Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company`s preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Website: virpaxpharma.com




Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company did not beat the estimated EPS.

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 24 880.1% (LTM)

Entry Point: Share price is 1 000.0% higher than minimum and 99.8% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: VRPX
Share price, USD:  (0.0%)0.011
year average price 0.1879  


year start price 0.2795 2025-02-07

max close price 2.0700 2025-03-21

min close price 0.0010 2025-12-19

current price 0.0110 2026-02-07
Common stocks: 1 461 558

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 0
Net Debt ($m): -31
EV (Enterprise Value): -31
Price to Book: 0.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-07-10investorplace.com

Why Is Virpax Pharmaceuticals (VRPX) Stock Up 98% Today?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol VRPX VRPX VRPX VRPX VRPX VRPX VRPX VRPX VRPX VRPX VRPX VRPX VRPX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
filingDate 2025-03-03 2024-10-10 2023-03-22 2022-03-31 2021-03-31
acceptedDate 2025-03-03 16:06:54 2024-11-14 17:00:42 2024-08-12 16:26:43 2024-05-13 16:02:37 2024-10-10 17:08:24 2023-12-07 08:50:05 2023-08-14 09:15:23 2023-05-12 16:15:38 2023-03-22 16:06:13 2022-11-09 16:06:17 2022-08-15 16:17:25 2022-03-31 16:06:46 2021-03-31 16:30:13
fiscalYear 2024 2023 2022 2021 2020
period FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
revenue 0 0 0 0 0 0 0 0 0 0 0 0 0
costOfRevenue 0 0 0 0 0 0 0 0 0 0 0 0 0
grossProfit 0 0 0 0 0 0 0 0 0 0 0 0 0
researchAndDevelopmentExpenses 5 819M 1M 2M 2M 5M 1M 1M 1M 11M 3M 3M 5M 1M
generalAndAdministrativeExpenses 6 261M 780 958 2M 2M 8M 5M 2M 415 451 11M 5M 3M 7M 3M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 6 261M 780 958 2M 2M 8M 5M 2M 415 451 11M 5M 3M 7M 3M
otherExpenses 0 0 0 82 033 3M 120 640 126 720 130 531 194 413 0 19 374 62 259 4000
operatingExpenses 12 080M 2M 3M 3M 16M 6M 3M 2M 22M 8M 6M 12M 4M
costAndExpenses 0 2M 3M 3M 16M 6M 3M 2M 22M 8M 6M 12M 4M
netInterestIncome 0 0 0 -92 729 -147 786
interestIncome 0 0 0 0 0 0 0 0 0 0 0 0 147.934
interestExpense -104M 92 748 11 002 0 0 0 0 -130 531 0 -73 252 0 92 822 147 934
depreciationAndAmortization 91M 10 650 19 128 3M 500 279 6115.138 3005.487 0 18M 73 252 0 12M 4M
ebitda -12 080M -2M -3M -3M -15M -6M -3M -2M 0 -8M -6M 0 4000
ebit -12 171M -15M -22M -12M -4M
nonOperatingIncomeExcludingInterest 91M -500 279 -194 410 -62 260 -4000
operatingIncome -12 080M -2M -3M -3M -16M -6M -3M -2M -22M -8M -6M -12M -4M
totalOtherIncomeExpensesNet 13M -82 102 8126 82 036 500 280 120 640 126 720 130 531 194 413 73 252 19 374 -30 563 -143 934
incomeBeforeTax -12 067M -2M -3M -3M -15M -6M -3M -2M -22M -8M -6M -12M -4M
incomeTaxExpense 0 0 0 -3M 0 -6115.138 -3005.487 -130 531 0 -73 252 0 0 0
netIncomeFromContinuingOperations -12 067M -15M -22M -12M -4M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncome -12 067M -2M -3M -3M -15M -6M -3M -1M -21M -8M -6M -12M -4M
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -12 067M -15M -22M -12M -4M
eps -2836.41 -0.43 -1.75 -2.75 -12.97 -5.12 -0.27 -0.12 -18.32 -0.65 -0.5 -10.37 -9.07
epsDiluted -2836.41 -12.97 -18.32 -10.37 -9.07
weightedAverageShsOut 4M 5M 2M 1M 1M 1M 12M 12M 1M 12M 12M 1M 494 515
weightedAverageShsOutDil 4M 5M 2M 1M 1M 1M 12M 12M 1M 12M 12M 1M 494 515
fillingDate 2024-11-14 2024-08-12 2024-05-13 2023-12-07 2023-08-14 2023-05-12 2022-11-09 2022-08-15
calendarYear 2024 2024 2024 2023 2023 2023 2022 2022
grossProfitRatio 0 0 0 0 0 0 0 0
ebitdaratio 0 0 0 0 0 0 0 0
operatingIncomeRatio 0 0 0 0 0 0 0 0
incomeBeforeTaxRatio 0 0 0 0 0 0 0 0
netIncomeRatio 0 0 0 0 0 0 0 0
epsdiluted -0.43 -1.75 -2.75 -5.12 -0.27 -0.12 -0.65 -0.5
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol VRPX VRPX VRPX VRPX VRPX VRPX VRPX VRPX VRPX VRPX VRPX VRPX VRPX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
filingDate 2025-03-03 2024-10-10 2023-03-22 2022-03-31 2021-03-31
acceptedDate 2025-03-03 16:06:54 2024-11-14 17:00:42 2024-08-12 16:26:43 2024-05-13 16:02:37 2024-10-10 17:08:24 2023-12-07 08:50:05 2023-08-14 09:15:23 2023-05-12 16:15:38 2023-03-22 16:06:13 2022-11-09 16:06:17 2022-08-15 16:17:25 2022-03-31 16:06:46 2021-03-31 16:30:13
fiscalYear 2024 2023 2022 2021 2020
period FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
cashAndCashEquivalents 2M 17 229 2M 2M 9M 12M 15M 17M 19M 21M 26M 37M 54 796
shortTermInvestments 1 512M 0 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 1 513M 17 229 2M 2M 9M 12M 15M 17M 19M 21M 26M 37M 54 796
netReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0
accountsReceivables 0 0 0 0 0
otherReceivables 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0
prepaids 0 203 463 182 095 161 254 17 738
otherCurrentAssets 43M 286 933 719 880 1M 283 370 885 394 1M 2M 496 270 3M 3M 3M 535
totalCurrentAssets 1 556M 304 162 3M 3M 10M 13M 16M 18M 20M 24M 29M 40M 73 069
propertyPlantEquipmentNet 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 0 0 0 0 0 0 0 0 0 0 0 0 392 337
totalNonCurrentAssets 0 0 0 0 0 0 0 0 0 0 0 0 392 337
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 1 556M 304 162 3M 3M 10M 13M 16M 18M 20M 24M 29M 40M 465 406
totalPayables 41 056 18 457 37 644 19 841 1M
accountPayables 0 0 75 399 2M 18 457 33.192 76.062 0 37 644 4M 0 19 841 22 107
otherPayables 41 056 0 0 0 2M
accruedExpenses 0 2M 1M 2M 1M
shortTermDebt 0 0 0 0 0 0 0 0 0 0 0 0 543 990
capitalLeaseObligationsCurrent 0 0 0 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 8000 8000 13 365
deferredRevenue 0 0 0 0 0 0 0 0 0 0 0 0 -1M
otherCurrentLiabilities 2 469M 2M 5M 3M 6M 7M 4M 3M 2M 0 2M 0 1M
totalCurrentLiabilities 2 469M 2M 5M 4M 8M 7M 4M 3M 3M 4M 2M 2M 4M
longTermDebt 0 0 0 0 0 0 0 0 0 0 0 0 1M
capitalLeaseObligationsNonCurrent 0 0 0 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 0 0 0 0 -4M 0 0 0
totalNonCurrentLiabilities 0 0 0 0 0 0 0 0 1094.59 4M 0 0 1M
otherLiabilities 0 0 0 0 0 0 0 0 -1094.59 -4M 0 0 0
capitalLeaseObligations 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilities 2 469M 2M 5M 4M 8M 7M 4M 3M 3M 4M 2M 2M 5M
treasuryStock 0 0 0 0 0
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 149 49 28 12 12 117 117 117 117 117 117 117 31
retainedEarnings -71 611M -68M -66M -63M -60M -55M -49M -46M -44M -41M -34M -23M -11M
additionalPaidInCapital 0 61M 61M 60M 6M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 -0 -0 0 0 0 -0 0 0 -0 0
otherTotalStockholdersEquity 70 698M 0 0 0 0
totalStockholdersEquity -914M -2M -3M -1M 2M 7M 12M 15M 17M 19M 27M 37M -4M
totalEquity -914M -2M -3M -1M 2M 7M 12M 15M 17M 19M 27M 37M -4M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 556M 304 162 3M 3M 10M 13M 16M 18M 20M 24M 29M 40M 465 406
totalInvestments 1 512M 0 0 0 0 0 0 0 0 0 0 0 0
totalDebt 0 0 0 0 0 0 0 0 0 0 0 0 2M
netDebt -2M -17 229 -2M -2M -9M -12M -15M -17M -19M -21M -26M -37M 2M
fillingDate 2024-11-14 2024-08-12 2024-05-13 2023-12-07 2023-08-14 2023-05-12 2022-11-09 2022-08-15
calendarYear 2024 2024 2024 2023 2023 2023 2022 2022
othertotalStockholdersEquity 66M 63M 62M 61M 61M 61M 61M 61M
totalLiabilitiesAndStockholdersEquity 304 162 3M 3M 13M 16M 18M 24M 29M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol VRPX VRPX VRPX VRPX VRPX VRPX VRPX VRPX VRPX VRPX VRPX VRPX VRPX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
filingDate 2025-03-03 2024-10-10 2023-03-22 2022-03-31 2021-03-31
acceptedDate 2025-03-03 16:06:54 2024-11-14 17:00:42 2024-08-12 16:26:43 2024-05-13 16:02:37 2024-10-10 17:08:24 2023-12-07 08:50:05 2023-08-14 09:15:23 2023-05-12 16:15:38 2023-03-22 16:06:13 2022-11-09 16:06:17 2022-08-15 16:17:25 2022-03-31 16:06:46 2021-03-31 16:30:13
fiscalYear 2024 2023 2022 2021 2020
period FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
netIncome -12M -2M -3M -3M -15M -6M -3M -2M -22M -8M -6M -12M -4M
depreciationAndAmortization 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredIncomeTax 0 0 0 0 0 0 0 0 0 0 0 0 0
stockBasedCompensation 135M -17 730 72 510 72 719 544 770 195 564 218 257 140 583 745 034 150 717 244 701 974 234 1M
changeInWorkingCapital -5M -2M 2M -5M 4M 3M 711 593 -628 416 3M 2M 904 014 -3M 1M
accountsReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0
accountsPayables 0 -223 809 1M -304 184 0 0 0 199 649 -993 101 2M 0 -686 776 1M
otherWorkingCapital -5M -2M 544 396 -5M 4M 3M 711 593 -199 649 4M 268 157 0 -3M -13 090
otherNonCashItems -16 831M 0 0 72 719 599 434 195 564 0 0 745 034 0 0 -61 816 153 222
netCashProvidedByOperatingActivities -16 713M -4M -2M -8M -10M -3M -2M -2M -18M -5M -5M -15M -1M
investmentsInPropertyPlantAndEquipment 0 0 -3 0 0 0 0 0 0 0 0 0 0
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivities 0 0 0 0 0
netCashProvidedByInvestingActivities 0 0 0 0 0
netDebtIssuance 0 0 0 -2M 72 100
longTermNetDebtIssuance 0 0 0 -2M 72 100
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 6M 0 0 58M 1M
netCommonStockIssuance 6M 0 0 58M 1M
commonStockIssuance 6M 0 0 58M 1M
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 9 078M 0 0 -5M -50 880
netCashProvidedByFinancingActivities 9 084M 0 0 51M 1M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash -7 628M -2M 4598 -7M -10M -3M -2M -2M -18M -5M -5M 37M 13 260
cashAtEndOfPeriod 1 513M 17 229 2M 2M 9M 12M 15M 17M 19M 21M 26M 37M 54 796
cashAtBeginningOfPeriod 9 142M 2M 2M 9M 19M 15M 17M 19M 37M 26M 31M 54 796 41 536
operatingCashFlow -16 713M -4M -2M -8M -10M -3M -2M -2M -18M -5M -5M -15M -1M
capitalExpenditure 0 0 -3 0 0 0 0 0 0 0 0 0 0
freeCashFlow -16 713M -4M -2M -8M -10M -3M -2M -2M -18M -5M -5M -15M -1M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0
fillingDate 2024-11-14 2024-08-12 2024-05-13 2023-12-07 2023-08-14 2023-05-12 2022-11-09 2022-08-15
calendarYear 2024 2024 2024 2023 2023 2023 2022 2022
otherInvestingActivites 0 0 0 0 0 0 0 0
netCashUsedForInvestingActivites 0 0 0 0 0 0 0 0
debtRepayment 0 0 -453 951 0 0 0 0 0
commonStockIssued -2M 2M 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0
otherFinancingActivites 3M 2M 453 951 0 0 0 0 0
netCashUsedProvidedByFinancingActivities 3M 2M 453 951 0 0 0 0 0
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Earning call transcript

SEC forms

Show financial reports only

SEC form 8
2025-03-21 21:20 ET
Virpax Pharmaceuticals, Inc. published news for 2024 q4
SEC form 8
2025-03-21 21:20 ET
Virpax Pharmaceuticals, Inc. published news for 2024 q4
SEC form 10
2025-03-03 21:06 ET
Virpax Pharmaceuticals, Inc. reported for 2024 q4
SEC form 10
2025-03-03 00:00 ET
Virpax Pharmaceuticals, Inc. reported for 2024 q4
SEC form 8
2025-01-30 21:04 ET
Virpax Pharmaceuticals, Inc. published news for 2024 q4
SEC form 8
2025-01-30 21:04 ET
Virpax Pharmaceuticals, Inc. published news for 2024 q4
SEC form 8
2025-01-30 21:04 ET
Virpax Pharmaceuticals, Inc. published news for 2024 q4
SEC form 8
2025-01-30 21:04 ET
Virpax Pharmaceuticals, Inc. published news for 2024 q4
SEC form 8
2025-01-30 21:04 ET
Virpax Pharmaceuticals, Inc. published news for 2024 q4
SEC form 8
2025-01-30 21:04 ET
Virpax Pharmaceuticals, Inc. published news for 2024 q4
SEC form 8
2025-01-30 21:04 ET
Virpax Pharmaceuticals, Inc. published news for 2024 q4
SEC form 8
2025-01-30 21:04 ET
Virpax Pharmaceuticals, Inc. published news for 2024 q4
SEC form 10
2024-11-14 17:00 ET
Virpax Pharmaceuticals, Inc. reported for 2024 q3
SEC form 10
2024-11-14 00:00 ET
Virpax Pharmaceuticals, Inc. reported for 2024 q3
SEC form 8
2024-08-13 00:00 ET
Virpax Pharmaceuticals, Inc. published news for 2024 q2
SEC form 8
2024-08-13 00:00 ET
Virpax Pharmaceuticals, Inc. reported for 2024 q2
SEC form 10
2024-08-12 00:00 ET
Virpax Pharmaceuticals, Inc. reported for 2024 q2
SEC form 8
2024-05-13 16:20 ET
Virpax Pharmaceuticals, Inc. reported for 2024 q1
SEC form 8
2024-05-13 16:20 ET
Virpax Pharmaceuticals, Inc. published news for 2024 q1
SEC form 10
2024-05-13 16:02 ET
Virpax Pharmaceuticals, Inc. reported for 2024 q1
SEC form 10
2024-05-13 00:00 ET
Virpax Pharmaceuticals, Inc. reported for 2024 q1
SEC form 10
2024-03-26 08:15 ET
Virpax Pharmaceuticals, Inc. reported for 2023 q4
SEC form 8
2024-03-26 07:30 ET
Virpax Pharmaceuticals, Inc. reported for 2023 q4
SEC form 8
2024-03-26 07:30 ET
Virpax Pharmaceuticals, Inc. published news for 2023 q4
SEC form 10
2024-03-26 00:00 ET
Virpax Pharmaceuticals, Inc. reported for 2023 q4
SEC form 10
2023-12-07 00:00 ET
Virpax Pharmaceuticals, Inc. reported for 2023 q3
SEC form 8
2023-11-16 16:51 ET
Virpax Pharmaceuticals, Inc. reported for 2023 q3
SEC form 10
2023-08-14 09:15 ET
Virpax Pharmaceuticals, Inc. reported for 2023 q2
SEC form 6
2023-08-14 09:05 ET
Virpax Pharmaceuticals, Inc. reported for 2023 q2
SEC form 10
2023-08-14 00:00 ET
Virpax Pharmaceuticals, Inc. reported for 2023 q2
SEC form 8
2023-08-14 00:00 ET
Virpax Pharmaceuticals, Inc. reported for 2023 q2
SEC form 6
2023-07-26 16:10 ET
Virpax Pharmaceuticals, Inc. published news for 2023 q2
SEC form 6
2023-06-21 16:17 ET
Virpax Pharmaceuticals, Inc. published news for 2023 q1
SEC form 6
2023-06-21 16:16 ET
Virpax Pharmaceuticals, Inc. published news for 2023 q1
SEC form 6
2023-06-07 16:06 ET
Virpax Pharmaceuticals, Inc. published news for 2023 q1
SEC form 10
2023-05-12 16:15 ET
Virpax Pharmaceuticals, Inc. reported for 2023 q1
SEC form 6
2023-05-12 16:10 ET
Virpax Pharmaceuticals, Inc. reported for 2023 q1
SEC form 8
2023-05-12 00:00 ET
Virpax Pharmaceuticals, Inc. reported for 2023 q1
SEC form 10
2023-05-12 00:00 ET
Virpax Pharmaceuticals, Inc. reported for 2023 q1
SEC form 6
2023-04-14 16:10 ET
Virpax Pharmaceuticals, Inc. published news for 2023 q1
SEC form 6
2023-03-28 20:00 ET
Virpax Pharmaceuticals, Inc. published news for 2022 q4
SEC form 6
2023-03-28 16:05 ET
Virpax Pharmaceuticals, Inc. published news for 2022 q4
SEC form 10
2023-03-22 16:06 ET
Virpax Pharmaceuticals, Inc. reported for 2022 q4
SEC form 6
2023-03-22 09:00 ET
Virpax Pharmaceuticals, Inc. reported for 2022 q4
SEC form 10
2023-03-22 00:00 ET
Virpax Pharmaceuticals, Inc. reported for 2022 q4
SEC form 8
2023-03-22 00:00 ET
Virpax Pharmaceuticals, Inc. reported for 2022 q4
SEC form 6
2023-03-13 09:11 ET
Virpax Pharmaceuticals, Inc. published news for 2022 q4
SEC form 6
2023-02-17 09:02 ET
Virpax Pharmaceuticals, Inc. published news for 2022 q4
SEC form 6
2022-12-29 16:10 ET
Virpax Pharmaceuticals, Inc. published news for 2022 q3
SEC form 10
2022-11-09 16:06 ET
Virpax Pharmaceuticals, Inc. reported for 2022 q3
SEC form 6
2022-11-09 09:05 ET
Virpax Pharmaceuticals, Inc. reported for 2022 q3
SEC form 8
2022-11-09 00:00 ET
Virpax Pharmaceuticals, Inc. reported for 2022 q3
SEC form 10
2022-11-09 00:00 ET
Virpax Pharmaceuticals, Inc. reported for 2022 q3
SEC form 10
2022-08-15 16:17 ET
Virpax Pharmaceuticals, Inc. reported for 2022 q2
SEC form 6
2022-08-15 09:10 ET
Virpax Pharmaceuticals, Inc. reported for 2022 q2
SEC form 10
2022-08-15 00:00 ET
Virpax Pharmaceuticals, Inc. reported for 2022 q2
SEC form 8
2022-08-15 00:00 ET
Virpax Pharmaceuticals, Inc. reported for 2022 q2
SEC form 6
2022-07-25 17:01 ET
Virpax Pharmaceuticals, Inc. published news for 2022 q2
SEC form 6
2022-06-27 16:30 ET
Virpax Pharmaceuticals, Inc. published news for 2022 q1
SEC form 6
2022-06-15 17:01 ET
Virpax Pharmaceuticals, Inc. published news for 2022 q1
SEC form 10
2022-05-16 16:10 ET
Virpax Pharmaceuticals, Inc. reported for 2022 q1
SEC form 6
2022-05-16 09:10 ET
Virpax Pharmaceuticals, Inc. published news for 2022 q1
SEC form 10
2022-05-16 00:00 ET
Virpax Pharmaceuticals, Inc. reported for 2022 q1
SEC form 8
2022-05-16 00:00 ET
Virpax Pharmaceuticals, Inc. reported for 2022 q1
SEC form 10
2022-03-31 16:06 ET
Virpax Pharmaceuticals, Inc. published news for 2021 q4
SEC form 6
2022-03-31 09:05 ET
Virpax Pharmaceuticals, Inc. published news for 2021 q4
SEC form 10
2022-03-31 00:00 ET
Virpax Pharmaceuticals, Inc. published news for 2021 q4
SEC form 8
2022-03-31 00:00 ET
Virpax Pharmaceuticals, Inc. published news for 2021 q4
SEC form 6
2022-03-15 16:30 ET
Virpax Pharmaceuticals, Inc. published news for 2021 q4
SEC form 6
2021-11-15 16:10 ET
Virpax Pharmaceuticals, Inc. published news for 2021 q3
SEC form 10
2021-11-15 16:05 ET
Virpax Pharmaceuticals, Inc. published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
Virpax Pharmaceuticals, Inc. published news for 2021 q3
SEC form 8
2021-11-15 00:00 ET
Virpax Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-08-10 09:05 ET
Virpax Pharmaceuticals, Inc. published news for 2021 q2
SEC form 10
2021-08-10 00:00 ET
Virpax Pharmaceuticals, Inc. published news for 2021 q2
SEC form 10
2021-08-09 20:34 ET
Virpax Pharmaceuticals, Inc. published news for 2021 q2
SEC form 6
2021-08-05 18:04 ET
Virpax Pharmaceuticals, Inc. published news for 2021 q2
SEC form 6
2021-08-05 18:01 ET
Virpax Pharmaceuticals, Inc. published news for 2021 q2
SEC form 6
2021-07-30 09:15 ET
Virpax Pharmaceuticals, Inc. published news for 2021 q2
SEC form 6
2021-05-18 08:11 ET
Virpax Pharmaceuticals, Inc. published news for 2021 q1
SEC form 10
2021-05-17 16:01 ET
Virpax Pharmaceuticals, Inc. published news for 2021 q1
SEC form 10
2021-05-17 00:00 ET
Virpax Pharmaceuticals, Inc. published news for 2021 q1
SEC form 6
2021-04-19 16:30 ET
Virpax Pharmaceuticals, Inc. published news for 2021 q1
SEC form 6
2021-04-13 16:30 ET
Virpax Pharmaceuticals, Inc. published news for 2021 q1
SEC form 10
2021-03-31 16:30 ET
Virpax Pharmaceuticals, Inc. published news for 2020 q4
SEC form 6
2021-02-16 19:19 ET
Virpax Pharmaceuticals, Inc. published news for 2020 q4
SEC form 6
2021-02-16 19:16 ET
Virpax Pharmaceuticals, Inc. published news for 2020 q4
SEC form 6
2021-02-16 19:14 ET
Virpax Pharmaceuticals, Inc. published news for 2020 q4
SEC form 6
2021-02-16 19:12 ET
Virpax Pharmaceuticals, Inc. published news for 2020 q4
SEC form 6
2021-02-16 19:11 ET
Virpax Pharmaceuticals, Inc. published news for 2020 q4
SEC form 6
2021-02-16 19:06 ET
Virpax Pharmaceuticals, Inc. published news for 2020 q4
SEC form 6
2021-02-16 19:05 ET
Virpax Pharmaceuticals, Inc. published news for 2020 q4
SEC form 6
2021-02-16 19:04 ET
Virpax Pharmaceuticals, Inc. published news for 2020 q4
SEC form 6
2021-02-16 19:03 ET
Virpax Pharmaceuticals, Inc. published news for 2020 q4
SEC form 6
2021-02-16 19:01 ET
Virpax Pharmaceuticals, Inc. published news for 2020 q4